Orthofix director gets 14,965 deferred stock units
HENNEMAN JOHN B III reported acquisition or exercise transactions in this Form 4 filing.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
HENNEMAN JOHN B III reported acquisition or exercise transactions in this Form 4 filing.
Orthofix Medical Inc. director John B. Henneman III received an equity award of 14,965 deferred stock units on common stock. The units were granted at no cash cost and vest in full on the first anniversary of the grant date, contingent on continued board service.
Each deferred stock unit represents a right to receive one share of Orthofix common stock, which will be delivered within 45 days after his service with the company ends. Following this award, Henneman holds 105,774 shares and units directly, including 48,347 deferred stock units that were previously reported.
Insights
Director received routine deferred stock unit grant as board compensation.
The filing shows Orthofix Medical director John B. Henneman III acquired 14,965 deferred stock units as a compensation award, with no cash paid per share. This is a standard non-cash equity grant rather than an open-market purchase or sale.
The units vest in one year, subject to continued service, and settle into common stock within 45 days after his service ends. After this grant, he directly holds 105,774 shares and units, including 48,347 previously reported deferred stock units, suggesting the transaction is routine relative to his overall position.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Common Stock | 14,965 | $0.00 | $0.00 |
Footnotes (2)
- F1. Represents an award of deferred stock units that vest in full on the first anniversary of the grant date, subject to the reporting person's service through such date. Each deferred stock unit represents a contingent right to receive one share of common stock of the issuer. Vested deferred stock units will settle and convert into common stock within 45 days of the reporting person's termination of service with the issuer.
- F2. Includes 48,347 previously reported deferred stock units.
Key Figures
Key Terms
deferred stock units financial
vest financial
termination of service financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Orthofix Medical (OFIX) director John B. Henneman III receive in this Form 4 filing?
How and when do the new deferred stock units for Orthofix Medical (OFIX) vest?
Is the Orthofix Medical (OFIX) Form 4 transaction an open-market buy or sell?
AI-generated analysis. How Rhea-AI works. Not financial advice.